J&J Bets $3.37B on In Vivo CAR-T With Sail Biomedicines Deal

Johnson & Johnson (JNJ) announced a strategic collaboration with Sail Biomedicines on July 29, 2026, committing $785 million in initial payments and securing an exclusive option to acquire the privately held company for an additional $2.58 billion. The total potential deal value reaches approximately $3.37 billion, making it the largest in vivo CAR-T transaction to date. JNJ stock closed at $265.53 on July 29, up from $266.73 the prior session, barely moving on the news as expected for a $400 billion market cap company.

The deal structure

The initial $785 million breaks down into a $465 million equity investment made through JJDC, Johnson & Johnson’s corporate venture arm, plus up to $140 million in development milestone payments. The $2.58 billion acquisition option gives J&J the right to buy Sail outright if the collaboration produces clinical results worth the price. The collaboration agreement runs through Janssen Biotech, a J&J subsidiary.

Sail is a Flagship Pioneering company, the same incubator that created Moderna. The Cambridge, Massachusetts biotech is building its platform on Endless RNA (eRNA), a proprietary RNA construct delivered via targeted nanoparticles. The idea is to reprogram a patient’s T cells into CAR-T cells directly inside the body, eliminating the apheresis, centralized manufacturing, and lymphodepletion that make traditional ex vivo CAR-T expensive and slow.

Why in vivo CAR-T matters

Traditional CAR-T therapy requires extracting a patient’s T cells, shipping them to a manufacturing facility, genetically engineering them, expanding them, and infusing them back. Vein-to-vein time runs three to six weeks. A single dose of Carvykti, J&J’s existing BCMA CAR-T partnered with Legend Biotech, costs $465,000. The process works for blood cancers where patients are dying and can tolerate the wait, but it is impractical for autoimmune diseases where the condition is chronic rather than immediately life-threatening.

In vivo CAR-T replaces all of that with an injection. Sail’s eRNA constructs are designed to be delivered via nanoparticle directly to T cells in the patient’s bloodstream, turning them into CAR-T cells on site. If it works, the cost and complexity of CAR-T drop dramatically, and the modality becomes viable for lupus, myositis, systemic sclerosis, and other autoimmune conditions where ex vivo CAR-T’s price tag is a non-starter. J&J framed the approach as “immune reset,” the idea that a single in vivo CAR-T dose could deplete pathogenic B cells and reset the immune system to a healthy state.

The competitive context

J&J is late to in vivo CAR-T but is entering at the largest deal size. Lilly acquired Kelonia Therapeutics for in vivo CAR-T in multiple myeloma. AstraZeneca acquired Esobiotech. Bristol Myers Squibb acquired Orbital Therapeutics. Gilead acquired Interius BioTherapeutics. Each of those deals gave the buyer an in vivo CAR-T platform, but none approached $3.37 billion in total potential value. The Sail deal signals that J&J sees in vivo CAR-T as a threat to its existing cell therapy franchise and is willing to pay to own the disruption rather than be disrupted by it.

J&J already competes with itself in myeloma. Carvykti, its approved BCMA CAR-T, competes with its own bispecifics TECVAYLI and TALVEY, which recently showed an 89% risk reduction in the Phase 3 MonumenTAL-6 trial. In vivo CAR-T could eventually make both ex vivo CAR-T and bispecific infusions obsolete for autoimmune indications, which is a much larger market than myeloma.

What to watch

Sail has no clinical data yet. The collaboration will advance Sail’s “vanguard” in vivo CAR-T program in autoimmune diseases, with additional programs planned across the platform. The key milestone is first-in-human data, which will determine whether J&J exercises the $2.58 billion option. Watch for J&J to report its Q2 2026 earnings, where management may provide more detail on the immunology pipeline strategy. For broader context on the CAR-T sector and the companies with near-term catalysts, see our CAR-T stocks analysis.